leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...2728293031323334353637...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Meningeal carcinomatosis with decreased visual acuity: a case report. (Pubmed Central) -  Dec 13, 2023   
    An autopsy showed no invasion of the optic nerve or surrounding tissues. As the frequency of complications of meningeal carcinomatosis in solid cancers is rare, it is crucial to actively suspect and make an early diagnosis.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Review, Journal:  Exploring the Promise of Second-Line Chemotherapy in Biliary Tract Tumours: A Glimpse into Novel Treatment Approaches. (Pubmed Central) -  Dec 9, 2023   
    Conversely, the NIFTY trial introduced nal-IRI (nanoliposomal irinotecan) plus 5-FU/LV (5-fluorouracil and leucovorin) as an alternative option, demonstrating substantial gains in progression-free and overall survival...While challenges persist, ongoing investigations offer hope for optimising second-line therapy for biliary tract tumours, promising improved outcomes for patients facing this disease. This review provides an overview of current facts and challenges when delivering second-line chemotherapy for advanced biliary tract tumours.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine. (Pubmed Central) -  Dec 9, 2023   
    However, there is no established correlation between oxaliplatin and drug-response prediction...However, clusterin induced apoptosis inhibition and cell survival, demonstrating a significant correlation with drug resistance. This study's findings are expected to contribute to increasing the accuracy of drug-response prediction in patient-derived APC mutant colorectal cancer organoids, thereby providing reliable precision medicine and improving patient survival rates.
  • ||||||||||  Journal:  Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. (Pubmed Central) -  Dec 9, 2023   
    In line with the clinical outcomes, we identified patient-specific sensitivities to the standard of care therapies (gemcitabine-paclitaxel and FOLFIRINOX) using a growth rate-based and normalized drug response metric...Furthermore, our in vitro organoid analysis indicated a correlation with the matched patient progression-free survival (PFS) compared to the current, conventional drug response readouts. This work not only provides valuable insights on the response complexity in PDAC, but it also highlights the potential applications (extendable to other tumor types) and clinical translatability of our approach in drug discovery and the emerging era of personalized medicine.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Dec 8, 2023   
    P2,  N=43, Completed, 
    This work not only provides valuable insights on the response complexity in PDAC, but it also highlights the potential applications (extendable to other tumor types) and clinical translatability of our approach in drug discovery and the emerging era of personalized medicine. Unknown status --> Completed | Trial completion date: Jan 2021 --> Jul 2023 | Trial primary completion date: Jan 2020 --> Dec 2022
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    New P2 trial:  Total Neoadjuvant Therapy in Rectal Cancer (clinicaltrials.gov) -  Dec 7, 2023   
    P2,  N=42, Recruiting, 
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer. (Pubmed Central) -  Dec 7, 2023   
    Notably, comparable mechanisms were observed upon treatment with the platinum-based chemotherapy regimen FOLFIRINOX, currently a first-line treatment option for PDAC. We thus suggest that drugs targeting ribosome biogenesis can improve the senescence anticancer response in pancreatic cancer.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Enrollment closed, Trial completion date, Trial primary completion date:  TRICE: Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM (clinicaltrials.gov) -  Dec 7, 2023   
    P2,  N=140, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023 Completed --> Active, not recruiting | Trial completion date: Dec 2022 --> Jun 2025 | Trial primary completion date: Dec 2020 --> Dec 2022
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in patients (pts) with metastatic colorectal cancer (mCRC). (Level 1, West Hall; Poster Bd # L10) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_826;    
    Further, the impact on outcome of 5 selected germline single nucleotide polymorphisms (SNPs) in 3 significant IRGs, SCG2 (rs600257, rs9283537), CRIP2 rs66717274, and AXIN2 (rs7591, rs2240308), was evaluated in genotyped (OncoArray, Illumina) samples of 451 pts from 2 clinical trials: FIRE-3 (FOLFIRI-bev, N = 107; FOLFIRI-cet, N = 129) and TRIBE (FOLFIRI-bev, N = 215)... Our results highlight important role for SCG2, CRIP2, and AXIN2 as prognostic and predictive biomarkers for first-line treatment in mCRC, with potential targeted agent- and pt
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Genome-wide association study (GWAS) and novel prognostic markers in metastatic colorectal cancer (mCRC). (Level 1, West Hall; Poster Bd # L2) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_818;    
    These results suggest that germline genetic variation in MLPH and TYR may affect mCRC prognosis via a mechanism that involves melanin and possibly the epithelial-mesenchymal transition. Note: Authors Millstein and Lenz contributed equally to this work.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    An online rectal cancer tumoroid biorepository: A resource to facilitate multimodal data integration. (Level 1, West Hall; Poster Bd # K7) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_803;    
    Integrating histopathological, clinicogenomic, and tumoroid response data, this expanding online resource provides a platform to identify valid biomarkers for patient treatment response. This publicly available biorepository built within cBioPortal is intuitive and flexible to accommodate and organize a wide range of data and has the potential to serve as an important resource in rectal cancer research.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
    Induction chemotherapy plus concomitant oxaliplatin-based chemoradiotherapy for locally advanced rectal cancer: A real world experience at San Raffaele Hospital. (Level 1, West Hall; Poster Bd # J10) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_789;    
    The first cycle of mXELOX (oxaliplatin 85 mg/m2 D1 Q14 plus capecitabine 825 mg/m2 BID) was administrated before RT (as induction CT); the other 2 cycles of mXELOX were administrated concurrent with RT, with capecitabine continued until the end of RT... Considering the low rate of toxicities and the comparable efficacy in terms of downstaging, pCR, probability of DFS and OS to other TNT regimens proposed in recent studies, our schedule of neoadjuvant CT/RT may represent a potential alternative to standard CT/RT in selected patients with LARC.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study. (Level 1, West Hall; Poster Bd # H7) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_768;    
    P2
    In this small study, excellent local control was demonstrated with no local recurrence after TME and 25% of pts remaining on NOM at the time of analysis. The 33% of subjects offered NOM is much lower than the published 74% in OPRA, suggesting that chemo followed by SCRT may not be the most optimal approach if organ preservation is the primary treatment aim.
  • ||||||||||  Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
    FOLFOXIRI  (Level 1, West Hall; Poster Bd # G3) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_745;    
    Clinical trial information: NCT04430738. Based on these results, FOLFOXIRI
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Retrospective analysis of the real-world demographics, clinical characteristics, and treatment patterns in metastatic CRC among patients treated with encorafenib in combination with cetuximab in the United States. (Level 1, West Hall; Poster Bd # E6) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_710;    
    Adults ?18 years old with ?1 claim for enco (first claim for enco on/after 4/1/2020) with concurrent cetux, as approved, or with EGFR panitumumab (pani), ?2 ICD-9/10 codes for malignancy of the colon or rectum ?30 days apart in the 1 year before index date, and ?1 day of pharmacy and medical continuous enrollment during the index date were included...Among the enco patients who had a previous treatment computed in claims, FOLFOX +/- bevacizumab (beva) and FOLFIRI + beva were the most common. This study provides current RW demographics, disease characteristics and treatment patterns among BRAF mCRC patients treated with enco in the US.